Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Wissenschaftliche/r Mitarbeiter/in, Klinik für Frauenheilkunde und Geburtshilfe
Aktuelle Veranstaltungen
-
WiSe 2025
- Anamnese Seminar für Blockpraktikanten (8. FS PV)
- Frauenheilkunde und Geburtshilfe (7. FS WA) (3. Semester des zweiten Studienabschnittes)
- Frauenheilkunde und Geburtshilfe (8. FS PV) (4. Semester des zweiten Studienabschnittes)
- Wahlfach: Praxis der gynäkologischen und geburtshilflichen Diagnostik (*)
- Gynäkologisches Seminar für Blockpraktikanten (PV)
- Seminar Geburtshilfe für Blockpraktikanten (8. FS PV)
Vergangene Veranstaltungen (max. 10)
-
SoSe 2025
- Frauenheilkunde und Geburtshilfe (8. FS PV) (4. Semester des zweiten Studienabschnittes)
- Frauenheilkunde und Geburtshilfe (7. FS WA) (3. Semester des zweiten Studienabschnittes)
- Anamnese Seminar für Blockpraktikanten (8. FS PV)
- Seminar Geburtshilfe für Blockpraktikanten (8. FS PV)
- Gynäkologisches Seminar für Blockpraktikanten (PV)
- Wahlfach: Praxis der gynäkologischen und geburtshilflichen Diagnostik (*)
-
WiSe 2024
- Frauenheilkunde und Geburtshilfe (7. FS WA) (3. Semester des zweiten Studienabschnittes)
- Anamnese Seminar für Blockpraktikanten (8. FS PV)
- Frauenheilkunde und Geburtshilfe (8. FS PV) (4. Semester des zweiten Studienabschnittes)
- Wahlfach: Praxis der gynäkologischen und geburtshilflichen Diagnostik (*)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer : AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialIn: Journal of Clinical Oncology (JCO), Jg. 41, 2023, Nr. 4, S. 893 – 902
-
p53 and p16 expression profiles in vulvar cancer : a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study groupIn: American Journal of Obstetrics and Gynecology (AJOG), Jg. 224, 2021, Nr. 6, S. 595.e1 – 595.e11DOI, Online Volltext (Open Access)
-
P193 p53 and p16 expression profiles identify three prognostically subgroups in vulvar cancer : a TMA based study by the AGO-CaRE-translational study group : Poster exhibition Day 2In: International Journal of Gynecological Cancer, Jg. 29, 2019, Nr. Suppl. 4, A 172
-
BRCA-like classification in ovarian cancer : Results from the AGO-TRi-trialIn: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. Suppl. 15, S. 5546
-
Spätfolgen der Sectioentbindung: Narbendefekte und Plazentationsstörungen : Vorbeugen, erkennen, behandelnIn: Der Gynäkologe, Jg. 50, 2017, Nr. 10, S. 785 – 792
-
The successful phase 3 niraparib ENGOTOVl 6/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC)In: Journal of Clinical Oncology (JCO), Jg. 35, 2017, Nr. Suppl. 15, 5560
-
B3-lesions of the breast and cancer risk - an analysis of mammography screening patientsIn: Molecular and Clinical Oncology, Jg. 4, 2016, Nr. 5, S. 705 – 708
-
Embryologically based radical hysterectomy as peritoneal mesometrial resection (PMMR) with pelvic and para-aortic lymphadenectomy for loco-regional tumor control in endometrial cancer : first evidence for efficacyIn: Archives of Gynecology and Obstetrics, Jg. 294, 2016, Nr. 1, S. 153 – 160DOI (Open Access)
-
Evaluation of a novel ELISA for the tumor-associated antigen CA 72-4 in patients with ovarian cancerIn: International Journal of Pharmacokinetics, Jg. 2, 2016, Nr. 4, S. FSO145DOI (Open Access)
-
ICG-gestützte Navigation bei der Chirurgie uteriner MalignomeIn: Der Gynäkologe, Jg. 49, 2016, Nr. 5, S. 373 – 380
-
Intraoperative navigation in robotically assisted compartmental surgery of uterine cancer by visualisation of embryologically derived lymphatic networks with indocyanine-green (ICG)In: Journal of Surgical Oncology, Jg. 113, 2016, Nr. 5, S. 554 – 559DOI (Open Access)
-
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerIn: The New England Journal of Medicine, Jg. 375, 2016, Nr. 22, S. 2154 – 2164DOI (Open Access)
-
Robotically assisted peritoneal mesometrial resection (PMMR) in endometrial cancer supported by ICG labeling of the compartmental lymphatic systemIn: Gynecologic Oncology Reports, Jg. 16, 2016, S. 24DOI (Open Access)
-
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3 trialIn: The Lancet Oncology, Jg. 17, 2016, Nr. 1, S. 78 – 89
-
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma : A phase II study of the AGO-study group (AGO-GYN8)In: Gynecologic Oncology, Jg. 140, 2016, Nr. 3, S. 450 – 456
-
Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-upIn: Archives of Gynecology and Obstetrics, Jg. 292, 2015, Nr. 5, S. 1117 – 1125
-
Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies : A comparison to PET/CTIn: European Journal of Radiology, Jg. 84, 2015, Nr. 11, S. 2097 – 2102
-
Integrated PET/MRI for whole-body staging of patients with primary cervical cancer : preliminary resultsIn: European Journal of Nuclear Medicine and Molecular Imaging, Jg. 42, 2015, Nr. 12, S. 1814 – 1824
-
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspectsIn: Archives of Gynecology and Obstetrics, Jg. 292, 2015, Nr. 6, S. 1367 – 1372
-
Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignanciesIn: Journal of Nuclear Medicine (JNM), Jg. 55, 2014, Nr. 12, S. 1930 – 1935DOI (Open Access)
-
Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis : a comparison to whole-body magnetic resonance imaging aloneIn: Investigative Radiology, Jg. 49, 2014, Nr. 12, S. 808 – 815
-
Temsirolismus in platinum-resistant ovarian cancer or advanced / recurrent endometrial cancer : a multicenter phase-II trial of the ago study group (AGO-GYN 8)In: International Journal of Gynecological Cancer, Jg. 24, 2014, Nr. 9 Suppl. 4, S. 1184 – 1185DOI, Online Volltext (Open Access)
-
The haplotype of three polymorphisms in the SATB1 promoter region impacts survival in breast cancer patientsIn: Oncology Letters, Jg. 7, 2014, Nr. 6, S. 2007 – 2012DOI, Online Volltext (Open Access)
-
„Robotic surgery“ in der Gynäkologie : Stand und AusblickIn: Der Gynäkologe, Jg. 47, 2014, Nr. 3, S. 184 – 190
-
Definition of compartment based radical surgery in uterine cancer-part I : therapeutic pelvic and periaortic lymphadenectomy by Michael höckel translated to robotic surgeryIn: ISRN Obstetrics and Gynecology, 2013, S. 297921
-
Definition of compartment-based radical surgery in uterine cancer : Modified radical hysterectomy in intermediate/high-risk endometrial cancer using peritoneal mesometrial resection (PMMR) by M Höckel translated to robotic surgeryIn: World Journal of Surgical Oncology, Jg. 11, 2013, S. 198DOI (Open Access)
-
Definition of compartment-based radical surgery in uterine cancer : radical hysterectomy in cervical cancer as 'total mesometrial resection (TMMR)' by M Höckel translated to robotic surgery (rTMMR)In: World Journal of Surgical Oncology, Jg. 11, 2013, S. 211DOI (Open Access)
-
Endometriumkarzinom operative Strategie und adjuvanz : Ein möglicher ParadigmenwechselIn: Der Gynäkologe, Jg. 46, 2013, Nr. 5, S. 339 – 344
-
Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX, clinicopathological markers and tumor cell dissemination in the blood and bone marrowIn: Molecular and Clinical Oncology, Jg. 1, 2013, Nr. 6, S. 1049 – 1054
-
Evaluation of risk recurrence in early breast cancer assessed by Oncotype DX and tumor cell dissemination to blood and bone marrowIn: Journal of Clinical Oncology (JCO), Jg. 31, 2013, Nr. Suppl. 15, S. e11516
-
Peritoneale mesometriale Resektion (PMMR) als Kompartiment-basierte Operation : Technik beim "intermediate/high risk" EndometriumkarzinomIn: Der Gynäkologe, Jg. 46, 2013, Nr. 10, S. 751 – 756
-
Utility of mesothelin, L1CAM and afamin as biomarkers in primary ovarian cancerIn: Anticancer Research, Jg. 33, 2013, Nr. 1, S. 329 – 336
-
Morbidity of inguinofemoral lymphadenectomy in vulval cancerIn: The Scientific World Journal, 2012, S. 341253
-
Circulating 20S proteasome in patients with non-metastasized breast cancerIn: Anticancer Research, Jg. 31, 2011, Nr. 6, S. 2197 – 2201(Open Access)
-
Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer : A pilot studyIn: Anticancer Research, Jg. 31, 2011, Nr. 10, S. 3623 – 3628
-
EpCAM-autoantibody levels in the course of disease of ovarian cancer patientsIn: Medical Oncology, Jg. 28, 2011, Nr. 2, S. 626 – 630
-
Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapyIn: Genes, Chromosomes and Cancer, Jg. 50, 2011, Nr. 8, S. 598 – 605
-
Molecular Profiling and Prognostic Relevance of Circulating Tumor Cells in the Blood of Ovarian Cancer Patients at Primary Diagnosis and After Platinum-Based ChemotherapyIn: International Journal of Gynecological Cancer, Jg. 21, 2011, Nr. 5, S. 822 – 830
-
The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancerIn: Gynecologic Oncology, Jg. 120, 2011, Nr. 2, S. 233 – 238
-
Impact of disseminated tumor cells in bone marrow on outcome of patients with primary ovarian cancerIn: Journal of Clinical Oncology (JCO), Jg. 28, 2010, Nr. Suppl. 15, S. e15545
-
The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasmsIn: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Jg. 18, 2010, Nr. 7, S. 343 – 347
-
Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancerIn: The International Journal of Biological Markers (IJBM), Jg. 24, 2009, Nr. 4, S. 223 – 229
-
The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.In: Anticancer Research, Jg. 29, 2009, Nr. 8, S. 3449 – 3452
-
The haplotype of two FSHR polymorphisms in ovarian cancer : A potential role of ethnology in risk modificationIn: Gynecologic Oncology, Jg. 112, 2009, Nr. 3, S. 486 – 489
-
Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancerIn: Gynecologic Oncology, Jg. 107, 2007, Nr. 2, S. 331 – 338
-
Angiogenesis gene variants as biomarkers for bevacizumab-induced toxicities : A translational subproject of the prospective randomized phase III trial AGO-OVAR 17In: International Journal of Gynecological Cancer. London: BMJ Publishing Group, Jg. 34, 2024, Nr. Suppl. 1, S. A497DOI, Online Volltext (Open Access)
-
Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC) : A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890)In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 39, 2021, Nr. 15_Suppl, S. 5501 – 5501DOI (Open Access)
-
Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment. Basel: Karger, Jg. 41, 2018, Nr. Suppl. 1, S. 90 – 91DOI (Open Access) -
Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1)In: International Journal of Gynecological Cancer. London: BMJ Publishing Group, Jg. 26, 2016, Nr. Suppl. 3, S. 194 – 195
-
The haplotype of three polymorphisms in the SATB1 promoter-region and impact on survival in breast cancer patientsIn: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 31, 2013, Nr. 15 Suppl., S. 584
-
Are mesothelin and L1CAM useful biomarkers in primary ovarian cancer patients?In: Journal of Clinical Oncology (JCO). Alexandria: American Society of Clinical Oncology (ASCO), Jg. 29, 2011, Nr. 15, Suppl., S. e15559
-
Primary tumor loss of heterozygosity proximal to M6P/IGF2R locus is predictive for the presence and persistence of disseminated tumor cells in the bone marrow of ovarian cancer patientsIn: Cancer Research. Philadelphia: American Association for Cancer Research (AACR), Jg. 71, 2011, Nr. 8, Suppl., S. 2217
-
Genetische und serologische Marker in Genese und Erkrankungsverlauf des OvarialkarzinomsDuisburg, Essen, 2010